Synthetic protein is in human clinical trials
Researchers have developed a novel synthetic protein to treat macular degeneration and other incurable eye diseases that lead to blindness in millions of people. It is the first drug of its kind and is currently in human trials.
Neovascular age-related macular degeneration (AMD) affects more than 200 million people worldwide. In addition, millions more with type-1 or type-2 diabetes are at risk of developing diabetic macular edema (DME). Both diseases currently have no cure.
The drug originated in the lab of Dr. Sachdev Sidhu, entrepreneur in residence researcher at the University of Waterloo’s School of Pharmacy. He led its development with AntlerA Therapeutics Inc., where he is a scientific co-founder, in partnership with EyeBio.
Read more on Waterloo News.